[Is Herceptin(®) (trastuzumab) by subcutaneous a mini revolution? Pharmaco-economic study].
Herceptin(®) injected by intravenous (IV) is one of the key treatment of breast cancer HER2+. The improvement of galenic form allowed a new way of administration, the sub-cutaneous way (SC), authorized by EMEA in 2013. This new way enables a 5-minute infusion, a fixed dose and a fixed volume of preparation. On 2012, saving-time and financial impacts were calculated by extrapolation of the IV way in a cancer treatment center. The study showed a preparing time-saving of 7.5min/loading dose and of 6.5min/maintenance dose, and a nurse time-saving of 4.5min/loading dose and 4.25min/maintenance dose. Moreover, it can be added a saving of consumable of 13,31€ per injection in case of monotherapy. The SC leads to a new adaptation and reorganization in the preparation of monoclonal antibodies and day hospitals.
Institut Bergonié, service pharmacie, 233, cours de l'Argonne, 33076 Bordeaux, France. Electronic address: vincent.lieutenant@hotmail.fr.
Vincent
V
Lieutenant
Institut Bergonié, service pharmacie, 233, cours de l'Argonne, 33076 Bordeaux, France.
Émilie
É
Toulza
Institut Bergonié, service pharmacie, 233, cours de l'Argonne, 33076 Bordeaux, France.
Martine
M
Pommier
Institut Bergonié, service pharmacie, 233, cours de l'Argonne, 33076 Bordeaux, France.
Barbara
B
Lortal-Canguilhem
D000279:Administration, Cutaneous; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage* / Q000191:economics; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000191:economics; D001943:Breast Neoplasms / Q000188:drug therapy*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D013997:Time Factors; D000068878:Trastuzumab
D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068878:Trastuzumab
Herceptin; Pharmaco-economic; Pharmaco-économique; Sous-cutanée; Subcutaneous